Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study-Reference-Cited by-同舟云学术

Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study

Published:2019-11-13 Issue:1 Volume:7 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Heppt Markus V.,Amaral Teresa,Kähler Katharina C.,Heinzerling Lucie,Hassel Jessica C.,Meissner Markus,Kreuzberg Nicole,Loquai Carmen,Reinhardt Lydia,Utikal Jochen,Dabrowski Evelyn,Gesierich Anja,Pföhler Claudia,Terheyden Patrick,Thoms Kai-Martin,Zimmer Lisa,Eigentler Thomas K.,Kirchberger Michael C.,Stege Henner M.,Meier Friedegund,Schlaak Max,Berking Carola

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-019-0800-0.pdf

Reference31 articles.

1. Mallone S, De Vries E, Guzzo M, Midena E, Verne J, Coebergh JW, Marcos-Gragera R, Ardanaz E, Martinez R, Chirlaque MD, et al. Descriptive epidemiology of malignant mucosal and uveal melanomas and adnexal skin carcinomas in Europe. Eur J Cancer. 2012;48(8):1167–75.

2. Doherty RE, Alfawaz M, Francis J, Lijka-Jones B, Sisley K. Genetics of Uveal Melanoma. In: Scott JF, Gerstenblith MR, editors. Noncutaneous Melanoma. Brisbane: Codon Publications; 2018.

3. Rantala ES, Hernberg M, Kivela TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 2019;29(6):561–8.

4. Steeb T, Wessely A, Ruzicka T, Heppt MV, Berking C. How to MEK the best of uveal melanoma: a systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma. Eur J Cancer. 2018;103:41–51.

5. Heppt MV, Steeb T, Schlager JG, Rosumeck S, Dressler C, Ruzicka T, Nast A, Berking C. Immune checkpoint blockade for unresectable or metastatic uveal melanoma: a systematic review. Cancer Treat Rev. 2017;60:44–52.

Cited by 112 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: A systematic review and meta-analysis;Human Vaccines & Immunotherapeutics;2024-07-14

2. A phase Ib randomized multicenter trial of isolated hepatic perfusion in combination with ipilimumab and nivolumab for uveal melanoma metastases (SCANDIUM II trial);ESMO Open;2024-07

3. Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events;Frontiers in Immunology;2024-06-10

4. Clinical and genetic characteristics of BAP1-mutated non-uveal and uveal melanoma;Frontiers in Immunology;2024-06-05

5. Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma;Journal for ImmunoTherapy of Cancer;2024-06